Seoul National University Hospital: "Choline Alfoscerate Does Not Increase Kidney Cancer Risk...No Preventive Effect Found"
Results from a 14-Year Follow-Up of 490,000 Adults
No Difference in Kidney Cancer Incidence Between User and Non-User Groups
Oncological Safety Confirmed: Choline Alfoscerate Does Not Increase Kidney Cancer Risk
A research team at Seoul National University Hospital analyzed big data from the National Health Insurance Service and found that choline alfoscerate, which is prescribed as a cognitive enhancer, does not increase the risk of developing kidney cancer. However, the preventive effect on kidney cancer reported with dietary choline was not observed in the pharmaceutical form.
Analysis Results of the Association Between Use of Collin Alpha-Soreate and the Risk of Renal Cancer. Source: Seoul National University Hospital
View original imageOn August 5, Seoul National University Hospital announced that the research team led by Professor Park Sangmin in the Department of Family Medicine selected individuals without a history of cancer diagnosis from among more than 8.23 million adults aged 50 and older who underwent national health check-ups in 2009 and 2010. After conducting propensity score matching, they tracked a total of approximately 490,000 people—81,970 in the choline alfoscerate user group and 409,801 in the non-user group—for up to 14 years and derived these results.
During the follow-up period, there were 280 cases of kidney cancer in the user group and 1,570 cases in the non-user group. When converted to incidence rates per 1,000 person-years, the rates were 0.30 cases in the user group and 0.32 cases in the non-user group, showing virtually no difference.
Even after adjusting for kidney cancer risk factors such as smoking, alcohol consumption, obesity, hypertension, and diabetes, there was no significant difference in the risk of kidney cancer between choline alfoscerate users and non-users. Additional analyses that considered prescription duration, cancer latency period, and subgroup analyses also produced consistent results.
Choline alfoscerate is a medication widely prescribed for patients with cognitive decline and Alzheimer’s disease. While previous studies suggested that dietary choline may be associated with a reduced risk of renal cell carcinoma, this study did not confirm the same effect for the pharmaceutical form of choline alfoscerate.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Professor Park said, "Through large-scale big data analysis based on the Korean population, we have confirmed the oncological safety of choline alfoscerate in that it does not increase the risk of kidney cancer. However, as there is no evidence to support its preventive effect on kidney cancer, additional studies targeting diverse populations are needed." The research findings were published in the latest issue of the international journal Cancer Epidemiology.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.